Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Saniona AB: Saniona's partner, Luc Therapeutics, nominates clinical candidate and initiates preclinical development in joint Ataxia program

Saniona AB
Posted on: 14 Aug 17

PRESS RELEASE

14 August 2017

Saniona, a leading biotech company in the field of ion channels, today announces that its collaboration partner, Luc Therapeutics, has initiated preclinical development for the drug candidate called CAD-1883 for ataxia.

"We are very pleased about reaching this major milestone in our research collaboration with Luc Therapeutics. Luc Therapeutics has initiated the pre-clinical development with the aim of initiating Phase 1 first man clinical studies in 2018. With this successful completion of the research program, we can now allocate our resources from the ataxia program to some of our other first in class research programs," says Jørgen Drejer, CEO of Saniona.

Luc Therapeutics will be responsible for further development of compounds identified under the Ataxia program.

Apart from being a shareholder of Luc Therapeutics, Saniona has rights to royalties on products commercialised by Luc Therapeutics under the Ataxia program.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 14 August 2017.

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes upa unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Capand has about 5,000 shareholders. The company's share is traded under the ticker SANION. Read more at www.saniona.com .

About Luc Therapeutics

Luc Therapeutics is a private biotechnology company based in Cambridge, MA and funded by Atlas Venture, Clal Biotechnology Industries (CBI) and Slater Technology Fund. The company is translating new understandings of human neurobiology into differentiated medicines for serious psychiatric and neurological diseases. Luc Therapeutics is developing novel therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders. NMDA receptors are essential components of the brain's cognitive engine, dynamic synaptic plasticity. In 2015 Luc Therapeutics entered into a License and Collaboration Agreement with Novartis to Accelerate Development of Its Program for the Treatment of Depression. Read more at www.luctherapeutics.com

20170814 - PR - Luc Therapeutics - UK


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Saniona AB via GlobeNewswire
HUG#2126947
GlobeNewswire
globenewswire.com

Last updated on: 15/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.